Sanofi - American Depositary Shares (NQ:SNY)

Regeneron and Sanofi Expand Global Alliance with Multiple Next-Generation, Long-Acting Immunology Antibodies

Performance

52-Week Range 23.5% below 52-week high

40.29

39.0752W Low 52.6852W High

1 Week 1.4% below 1-week high

39.071W Low 40.871W High

Sanofi - American Depositary Shares (SNY) traded between $39.07 and $52.68 over the past 52 weeks and last traded at $40.29, 23.5% below its 52-week high. Over the past week it ranged between $39.07 and $40.87.

Past 12 Months

+0.5%

-5.0%

-8.9%

-15.6%

-16.5%

-17.7%

1W +$0.22

1M -$2.11

3M -$3.92

6M -$7.43

YTD -$7.94

1Y -$8.67

SNY was -17.7% over the past year, -15.6% over six months, -16.5% year to date, +0.5% in the last week.

12 Months vs Market

SNY

-17.7%

DIA

+12.6%

SPY

+16.0%

QQQ

+20.9%

IWM

+9.9%

Over the past 12 months SNY returned -17.7% versus DIA (Dow) +12.6%, SPY (S&P 500) +16.0%, QQQ (Nasdaq 100) +20.9% and IWM (Russell 2000) +9.9%.

Volume & Liquidity 1.70× 3-mo avg

Today 5,053,611 3-mo avg 3.0M

3.9M

3.3M

3.0M

3.1M

YTD

3.4M

3.2M

SNY most recently traded 5,053,611 shares against a 3-month average daily volume of 3.0M.

More News

October 01, 2026

From Regeneron Pharmaceuticals, Inc.

Via GlobeNewswire

Is Regeneron Stock a Bargain Below $800? ↗

September 22, 2026

SANOFI-ADR (NASDAQ:SNY): A Decent Value Stock With Strong Fundamentals and an Undervalued Profile ↗

Sanofi-ADR (NASDAQ:SNY): A Dividend Quality Candidate with Solid Profitability ↗

August 27, 2026

Via Chartmill

Sanofi (NASDAQ:SNY) Screens as Undervalued Value Stock with Solid Profitability ↗

August 07, 2026

Via Chartmill

Sanofi-ADR (NASDAQ:SNY) Offers a High Dividend Yield With Strong Underlying Quality ↗

July 16, 2026

Via Chartmill

July 13, 2026

Via Chartmill

Sanofi Reviews Pipeline, Broadens Deal Hunt as It Rebuilds Research Engine ↗

September 22, 2026

Sanofi Eyes €25B Dupixent Future, Expands M&A Hunt Ahead of Patent Loss ↗

September 20, 2026

A Micro-Cap Biotech Just Cleared a Milestone Most Never Reach

September 08, 2026

InvestorNewsBreaks – Quantum BioPharma Ltd. (NASDAQ: QNTM) Gains Editorial Spotlight Following FDA Clearance for Lucid-MS Phase 2 Trial

September 08, 2026

InvestorNewsBreaks – Quantum BioPharma Ltd. (NASDAQ: QNTM) (CSE: QNTM) Gains Editorial Spotlight Following FDA Clearance for Lucid-MS Phase 2 Trial

September 08, 2026

MissionIRNewsBreaks – Quantum BioPharma Ltd. (NASDAQ: QNTM) (CSE: QNTM) Gains Editorial Spotlight Following FDA Clearance for Lucid-MS Phase 2 Trial

September 08, 2026

Vertex vs. Regeneron: Which Biotech Giant Is the Better Buy Right Now? ↗

September 04, 2026

Sanofi Boasts a Dividend Yield of 5.4%, Trades Below 9x Earnings, and Just Got an FDA Win. Are Income Investors Missing a Rare Opportunity? ↗

A Micro-Cap Biotech Just Cleared a Milestone Most Never Reach

September 08, 2026

From BioMedWire

Via GlobeNewswire

August 26, 2026

Sanofi Q2 Earnings Call Highlights ↗

July 30, 2026

The Smartest Dividend Stock to Buy With $1,000 Right Now (Spoiler: It Yields 5.6%.) ↗

July 28, 2026

Next-Generation Diabetes Therapies Are Reshaping Healthcare and Creating MultiBillion-Dollar Revenue Opportunities

July 21, 2026

Via FinancialNewsMedia

3 High-Yield Dividend Stocks to Buy and Hold ↗

July 17, 2026

2 Fast-Growing Pharmaceutical Stocks to Buy Now ↗

July 08, 2026

Bargain Hunters: These 3 High-Yielding Stocks Recently Hit New 52-Week Lows ↗

June 30, 2026

MissionIRNewsBreaks – Quantum BioPharma Ltd. (NASDAQ: QNTM) (CSE: QNTM) Advances Novel Multiple Sclerosis Therapy Toward Phase 2 Trials

June 22, 2026

Novel Patented Myelin Drug-Discovery Strategy Targets Massive Unmet Need in Multiple Sclerosis

June 22, 2026